For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse BLINCYTO[®]—because his dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.^{1,2}

ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

References: 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843-854. 2. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO[®] is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.

API available Upon Request





For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse

BLINCYTO[®]—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.^{1,2}

ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.

References: 1. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843-854. **2.** Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO® is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.



API available Upon Request





For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse


A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.


ALL, acute lymphoblastic leukemia; AYA, adolescent and young adult; BiTE, Bispecific T-cell Engager.


Reference: Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833-842.

BLINCYTO[®] is a registered trademark of Amgen Inc. © 2021 Amgen Inc. All rights reserved.

BLINCYTO[®]—because her dreams are bigger than ALL









API available Upon Request





Age group 5-11

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse BLINCYTO®—because his dreams are bigger than ALL A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.^{1,2} and the second second **BLINCYTO** (blinatumomab) infusion

For pediatric and AYA patients with high-risk B-cell precursor ALL in first relapse BLINCYTO[®]—because her dreams are bigger than ALL

A targeted immunotherapy powered by BiTE® technology, BLINCYTO® offers a chemo-minimizing approach that significantly improves survival and offers fewer and less severe toxicities versus additional chemotherapy.^{1,2}



Age group 12-18

Age group 19-30

